Dirk van Lier

7PUBLICATIONS
6CO-AUTHORS
Toxicology (incl. clinical toxicology)Proteins and peptidesCardiology (incl. cardiovascular diseases)Artificial life and complex adaptive systemsRespiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 21, 2026
Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primates.

|May 21, 2026
Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.

|May 21, 2026
Development and non-clinical characterization of Procizumab (invobenitug): a humanized antibody neutralizing circulating DPP3.

|Jan 11, 2023
Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre study.

Dirk van Lier, Benjamin Deniau, Karine Santos

|Mar 19, 2021
Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patients.

Dirk van Lier, Matthijs Kox, Karine Santos

|Dec 31, 2020
Promotion of vascular integrity in sepsis through modulation of bioactive adrenomedullin and dipeptidyl peptidase 3.

D van Lier, M Kox, P Pickkers

Pageof 2

Frequent Collaborators

2 joint publications

Matthijs Kox

2 joint publications

Peter Pickkers

1 joint publications

Marieke Voet

1 joint publications

Joris Lemson